The new federal grant offers hope that the Missouri Technology Corp. can once again be a catalyst for dozens of promising startups each year.
Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...